NO RESISTANCE TO TENOFOVIR ALAFENAMIDE ( TAF) IN ADULT, HBEAG- POSITIVE AND HBEAG- NEGATIVE PARTICIPANTS WITH CHRONIC HEPATITIS B INFECTION TREATED WITH TAF FOR UP TO 8 YEARS.

被引：0
|
作者：
Mateo, Roberto [1 ]
Chan, Henry Lik Yuen [2 ]
Marcellin, Patrick [3 ]
Pan, Calvin Pan [4 ]
Yazdi, Tahmineh [1 ]
Chang, Silvia [1 ]
Han, Dong [1 ]
May, Lindsey [1 ]
Marceau, Caleb [1 ]
Richards, Christopher [1 ]
Manhas, Savrina [1 ]
Ho, Pui Yan [1 ]
Li, Robert [1 ]
Xu, Simin [1 ]
Martinez, Clarissa [1 ]
Liu, Yang [1 ]
Peinovich, Nadine [1 ]
Lopez, Andrew [1 ]
Abramov, Frida [1 ]
Flaherty, John F. [1 ]
Mo, Hongmei [1 ]
Izumi, Namiki [5 ]
Buti, Maria [6 ,7 ]
Dr Shalimar [8 ]
Lim, Young-Suk [9 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[3] Beaujon Hosp, Clichy, France
[4] NYU, Grossman Sch Med, New York, NY USA
[5] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan
[6] Hosp Univ Vall Dhebron, Barcelona, Spain
[7] Inst Carlos III, Ciberehd, Barcelona, Spain
[8] All India Inst Med Sci, New Delhi, India
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1430-C
引用
收藏
页码：S532 / S533
页数：2
相关论文
共 50 条
  • [21] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY
    Agarwal, Kosh
    Fung, Scott
    Seto, Wai-Kay
    Lim, Young-Suk
    Gane, Edward
    Janssen, Harry L.
    Chuang, Wan-Long
    Bae, Ho
    Yoon, Ki Tae
    Flaherty, John F.
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Cathcart, Andrea
    Lin, Lanjia
    Chan, Alain
    Shalimar, Mani Subramanian
    Furusyo, Norihiro
    Buti, Maria
    Chan, Henry L.
    GASTROENTEROLOGY, 2017, 152 (05) : S1085 - S1086
  • [22] HBeAg levels at week 24 predict response to 8years of tenofovir in HBeAg-positive chronic hepatitis B patients
    Wong, D.
    Littlejohn, M.
    Yuen, L.
    Jackson, K.
    Mason, H.
    Bayliss, J.
    Rosenberg, G.
    Gaggar, A.
    Kitrinos, K.
    Subramanian, M.
    Marcellin, P.
    Buti, M.
    Janssen, H. L. A.
    Gane, E.
    Locarnini, S.
    Thompson, A.
    Revill, P. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (01) : 114 - 122
  • [23] NO DETECTED RESISTANCE TO TENOFOVIR ALAFENAMIDE ( TAF) THROUGH 96 WEEKS OF TREATMENT IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B
    Rosenthal, Philip
    Chang, Mei-Hwei
    Bezerra, Jorge A.
    Liu, Yang
    Han, Dong
    Xu, Simin
    Marceau, Caleb
    Yazdi, Tahmineh
    May, Lindsey
    Li, Robert
    Manhas, Savrina
    Ho, Pui Yan
    Martinez, Clarissa
    Peinovich, Nadine
    Chang, Silvia
    Martin, Ross
    Maiorova, Evguenia
    Mo, Hongmei
    Abramov, Frida
    Flaherty, John F.
    Schwarz, Kathleen B.
    HEPATOLOGY, 2023, 78 : S531 - S532
  • [24] Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
    Long, Jianfei
    Gong, Jingru
    Zhu, Han
    Liu, Xiaolin
    Li, Ling
    Chen, Bicui
    Ren, Hongyan
    Liu, Chao
    Lu, Huiping
    Zhang, Jiming
    Wang, Bin
    FRONTIERS IN MICROBIOLOGY, 2023, 14
  • [25] PLASMA HEPCIDIN AND HAPTOGLOBIN CONCENTRATION PREDICTS PEGYLATED INTERFERON A-2B TREATMENT RESPONSE IN HBEAG- NEGATIVE CHRONIC HEPATITIS B PATIENTS
    Liang, Jing
    Tang, Fei
    Wang, Fengmei
    HEPATOLOGY, 2024, 80 : S227 - S228
  • [26] CURRENT MANAGEMENT AND TREATMENT INDICATIONS OF BASELINE GREY- ZONE ( GZ) PATIENTS WITH HBEAG- NEGATIVE CHRONIC HEPATITIS B VIRUS INFECTION ( CHBVE-) IN GREECE
    Papatheodoridi, Margarita
    Paraskevopoulou, Sofia
    Ioannidou, Panagiota
    Fytili, Paraskevi
    Karagiannakis, Dimitrios
    Cholongitas, Evangelos
    Vlachogiannakos, Ioannis
    Papatheodoridis, George
    HEPATOLOGY, 2024, 80 : S197 - S198
  • [27] Two year safety and tolerability of tenofovir disoproxil fumarate treatment in HBeAg negative and HBeAg positive patients with chronic hepatitis B
    Gane, E. J.
    Sievert, W.
    Weilert, F.
    George, J.
    Strasser, S. I.
    Crawford, D.
    Moyes, C.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A309 - A309
  • [28] LONG- TERM OUTCOMES OF BASELINE GREY- ZONE ( GZ) PATIENTS WITH HBEAG- NEGATIVE CHRONIC HEPATITIS B VIRUS INFECTION ( CHBVE-) IN GREECE
    Papatheodoridi, Margarita
    Paraskevopoulou, Sofia
    Ioannidou, Panagiota
    Fytili, Paraskevi
    Karagiannakis, Dimitrios
    Cholongitas, Evangelos
    Vlachogiannakos, Ioannis
    Papatheodoridis, George
    HEPATOLOGY, 2024, 80 : S198 - S198
  • [29] THREE YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B, PRELIMINARY ANALYSIS
    Lee, Samuel S.
    Heathcote, E. Jenny
    Sievert, William
    Trinh, Huy N.
    Kaita, Kelly D.
    Younossi, Zobair M.
    George, Jacob
    Shiffman, Mitchell L.
    Marcellin, Patrick
    Sorbel, Jeff
    Anderson, Jane
    Mondou, Elsa
    Ouinn, Joe
    Rousseau, Franck
    HEPATOLOGY, 2009, 50 (04) : 538A - 538A
  • [30] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results
    Strasser, S.
    Roberts, S.
    Angus, P.
    Chan, H. L. Y.
    Fung, S.
    Seto, W. K.
    Chuang, W. L.
    Chen, C. Y.
    Kim, H. J.
    Hui, A. J.
    Janssen, H. L. A.
    Chowdhury, A.
    Tsang, T. Y. O.
    Mehta, R.
    Gane, E.
    Flaherty, J. F.
    Massetto, B.
    Kitrinos, K.
    Dinh, P.
    Subramanian, G. M.
    Mchutchison, J. G.
    Lim, Y. S.
    Acharya, S. K.
    Agarwal, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 82 - 82
12345